Sponsor:
University of Calgary
Code:
NCT05775965
Conditions
Hip Fractures
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Rivaroxaban 10mg
acetylsalicylic acid (ASA) 81mg Oral Tablet
Brief summary:
Conditions
Hip Fractures
Study ID
NCT05775965
Start date
May 21, 2024
Status verified date
Sep, 2024
Completion date
Mar 1, 2026
Anticipated
Primary completion date
Mar, 2025
Anticipated
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Enrollment
250 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Rivaroxaban 10mg
experimental: acetylsalicylic acid (ASA) 81mg daily
Interventions
Rivaroxaban 10mg
acetylsalicylic acid (ASA) 81mg Oral Tablet
Primary outcome measure
Central contacts
Locations
Foothills Medical Centre
Recruiting
Calgary, Alberta, Canada, T2N 5A1
Contacts
Jessica Duong
jduong@ucalgary.caSponsor
University of Calgary
Last update posted
Jan 14, 2025
Last verified
Sep, 2024
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Calgary on 2025-01-14.